Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the ...

Delcath Systems announced the exercise of 1.7 million Series E and E1 warrants, resulting in $16.3 million in funding. This financial boost positions Delcath to strengthen its commercialization ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the ...

We feel now is a pretty good time to analyse Delcath Systems, Inc.'s ( NASDAQ:DCTH ) business as it appears the ...

Delcath Systems (DCTH) (ISIN: US24661P8077)股票专题，提供今日Delcath Systems(DCTH) (ISIN: US24661P8077)股票最新股价查询，实时市场行情，走势图表，及Delcath Systems(DCTH) (ISIN: US24661P8077)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of NASDAQ DCTH opened at $12.22 on Tuesday. The firm’s 50-day moving average price is $10.55 and its 200-day moving average price is $9.17. Delcath Systems, Inc. has a 52-week low of $3. ...

On Thursday, Delcath Systems Inc. (NASDAQ:DCTH), a specialized interventional oncology company, received a Buy rating from Clear Street, with a price target set at $22.00. This aligns with the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...